{"id":"sodas-mph","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness or anxiety"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SODAS MPH (Spheroidal Oral Drug Absorption System) uses a proprietary microencapsulation technology to deliver methylphenidate in a biphasic release pattern—an initial immediate release followed by a sustained release phase. This allows for once-daily dosing while maintaining consistent plasma concentrations of the stimulant, which enhances dopamine and norepinephrine availability in the central nervous system to improve attention and impulse control.","oneSentence":"SODAS MPH is a sustained-release formulation of methylphenidate designed to provide extended therapeutic coverage for attention-deficit/hyperactivity disorder (ADHD) symptoms throughout the day.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:49.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"}]},"trialDetails":[{"nctId":"NCT01673594","phase":"PHASE4","title":"Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-09","conditions":"ADHD, Stimulant-Induced Euphoria","enrollment":37},{"nctId":"NCT00302354","phase":"PHASE4","title":"A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT00536419","phase":"PHASE4","title":"Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2007-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ritalin LA"],"phase":"marketed","status":"active","brandName":"SODAS MPH","genericName":"SODAS MPH","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SODAS MPH is a sustained-release formulation of methylphenidate designed to provide extended therapeutic coverage for attention-deficit/hyperactivity disorder (ADHD) symptoms throughout the day. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}